At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
SB623biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke
In Brief
A Phase 2 clinical trial evaluating SB623 for Chronic Ischemic Stroke. Completed, enrolled 18 participants across 5 sites.
Detailed Summary
The primary purpose of the clinical study is to determine the safety of a modified stem cell SB623 when administered to chronic, stable ischemic stroke patients. A second purpose is to determine whether SB623 might improve stroke symptoms. Chronic, stable ischemic stroke patients must be between 6 and 60 months after their stroke, and with only this one prior stroke, and with no further improvement from physical therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Ischemic Stroke
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedFeb 2011
Primary CompletionAug 2015
TodayJul 2026
First PostedFeb 2, 2011
Enrollment StartJan 1, 2011
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.4 years ago
Interventions
SB623biological
SB623, a modified stem-cell product